Radiation Oncology
Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.
Recent Discussions
Would you offer re-irradiation for an upper GI bleed secondary to a necrotic, intraluminal gastric Merkel cell metastasis previously treated with 50 Gy in 25 fractions roughly one year ago?
Absolutely. 30 Gy in 20 fx @1.5 Gy BID. I would consider 36 Gy or even 39 Gy @1.5 Gy BID for smaller volumes or longer intervals (>2 yr). Notably, the cardia is more resistant, and the antrum is most sensitive. The body is probably more like the antrum. If BID fractionation is not feasible, I would ...
When should you use single-fraction radiotherapy for spinal cord compression?
The SCORAD III trial is practice changing. But I do NOT plan to treat ALL patients with spinal cord compression with a single fraction of 8 Gy now. Here is why: SCORAD III is extremely important new study for the management of metastatic epidural spinal cord compression (MESCC) for patients with sho...
How do you approach palliative RT dose selection to skeletal lesions in patients with Myeloma who are actively receiving or likely to need systemic therapy?
Multiple myeloma patients with painful bone disease often present a unique constellation of clinical characteristics, such as extensive skeletal involvement, longer life expectancies, and many prior or anticipated systemic treatments. Some key features influencing my choice of radiation dose and sch...
Do you use either memantine or hippocampal sparing technique to preserve cognitive function when giving whole brain radiotherapy?
Dr. @Dr. First Last and I put together the response below:We use memantine and hippocampal sparing technique for all brain metastasis patients who are planning to receive WBRT. This is based off the recently published phase III trial NRG CC001 that found hippocampal avoidance WBRT plus memantine res...
Is there a correlation between rectal cancer stage and dose response to radiotherapy?
Possibly. While some compelling data from Appelt et al. in 2013 reflected there may be a correlation between RT dose and rectal tumor response (Appelt et al., PMID 22763027), an extensive number of prospective trials examining the influence of boost doses of RT on pathologic response have produced m...
Are CHEK2 mutations a contraindication for breast conservation therapy with lumpectomy + RT?
Among women with early-stage breast cancer and moderate penetrance breast cancer susceptibility genes, such as CHEK2, decisions about breast surgery are largely based upon personal preferences. According to data from large population-based studies, women with CHEK2 pathogenic variants have about a 2...
How do you approach treatment of a glioblastoma in pregnancy?
Glioblastoma during pregnancy could be treated safely (to mother and fetus) with certain precautions and modifications. Collaboration and consultation with the patient’s obstetrician are essential. External shielding over the patient’s abdomen during treatment will decrease the external scatter radi...
How do you talk to patients with intermediate-risk prostate cancer deciding between LDR brachytherapy (monotherapy) vs HDR mono vs SBRT vs EBRT, in terms of the comparative side effect profile of each approach?
It’s hard to add much to Dr. @Dr. First Last's excellent evidence-based answer, but I’ll elaborate on the counseling aspect from my perspective. Introduction: I start by acknowledging how difficult it is to weigh several totally foreign options and acknowledge the gravity of the decision. My patient...
Is long term ADT now the standard of care with salvage prostate bed RT?
The dreaded hormone question...After 40 years of embarking on extremely well designed randomized trials, we still are confused about the who, what, when of ADT. Will RTOG 9601 create a new care standard? As @Dr. First Last said, I think we will see increased utilization. I have been using bicalutami...
Would you consider radiotherapy for an unresectable 4 cm functional adrenal pheochromocytoma that is growing slowly but is not metastatic?
Yes, ablative dose 50 Gy in 5# radiation with DIBH soft tissue IGRT motion management. This area is typically not near luminal structures, but 67.5 Gy in 15 # would be preferred. These doses result in excellent control; lower doses may not. The tumor will typically not remain functional.